News

MULTIMEDIA: Vemurafenib -- Melanoma Drug Cuts Death Risk

Publish date: August 10, 2011
By
Therese Borden

 

This drug works by attacking a specific genetic mutation, BRAF V600E, that accelerates tumor growth.

<a href="http://storify.com/taborden/vemurafenib-gives-melanoma-patients-new-hope" target="_blank">View "Vemurafenib" on Storify</a>

Recommended Reading

Short-Term ADT with Radiotherapy Ups Prostate Cancer Survival
MDedge Hematology and Oncology
Obesity, Estrogen Status Influence Breast Cancer Outcomes
MDedge Hematology and Oncology
Triptorelin Cuts Early Menopause in Breast Cancer
MDedge Hematology and Oncology
Mutations Linked to Esophageal Adenocarcinoma, Barrett's Esophagus
MDedge Hematology and Oncology
Occult Sentinel Node Metastases Don't Impact Survival
MDedge Hematology and Oncology
Stereotactic Radiation Gives Elderly Lung Cancer Patients an Alternative to Surgery
MDedge Hematology and Oncology
ASCO Calls for Oncology-Based Medical Homes
MDedge Hematology and Oncology
CAD Software Does Not Improve Mammogram Accuracy
MDedge Hematology and Oncology
Paraneoplastic Autoimmune Multiorgan Syndrome Proves Rapidly Fatal
MDedge Hematology and Oncology
Platinum-Based Chemotherapy Benefits Elderly Lung Cancer Patients
MDedge Hematology and Oncology

Related Articles